BACKGROUND: Recombinant vesicular stomatitis virus expressing interferon-β (VSV-IFN-β) has demonstrated antitumor activity in vitro and in vivo. In preparation for clinical testing in human squamous cell carcinoma (SCC) of the head and neck, we conducted preclinical studies of VSV-IFN-β in syngeneic SCC models. METHODS: In vitro, VSV-IFN-β (expressing rat or mouse interferon [IFN]-β)-induced cytotoxicity and propagated in rat (FAT-7) or mouse (SCC-VII) SCC cells during normoxia and hypoxia. In vivo, intratumoral administration of VSV-rat-IFN-β or VSV-human-IFN-β in FAT-7 bearing or non-tumor bearing immunocompetent rats did not result in acute organ toxicity or death. RESULTS: VSV-r-IFN-β replicated predominantly in tumors and a dose dependent anti-VSV antibody response was observed. Intratumoral or intravenous administration of VSV-IFN-β resulted in growth delay and improved survival compared with controls. CONCLUSION: The above data confirm safety and feasibility of VSV-IFN-β administration in immunocompetent animals and support its clinical evaluation in advanced human head and neck cancer.
BACKGROUND: Recombinant vesicular stomatitis virus expressing interferon-β (VSV-IFN-β) has demonstrated antitumor activity in vitro and in vivo. In preparation for clinical testing in humansquamous cell carcinoma (SCC) of the head and neck, we conducted preclinical studies of VSV-IFN-β in syngeneic SCC models. METHODS: In vitro, VSV-IFN-β (expressing rat or mouse interferon [IFN]-β)-induced cytotoxicity and propagated in rat (FAT-7) or mouse (SCC-VII) SCC cells during normoxia and hypoxia. In vivo, intratumoral administration of VSV-rat-IFN-β or VSV-human-IFN-β in FAT-7 bearing or non-tumor bearing immunocompetent rats did not result in acute organ toxicity or death. RESULTS:VSV-r-IFN-β replicated predominantly in tumors and a dose dependent anti-VSV antibody response was observed. Intratumoral or intravenous administration of VSV-IFN-β resulted in growth delay and improved survival compared with controls. CONCLUSION: The above data confirm safety and feasibility of VSV-IFN-β administration in immunocompetent animals and support its clinical evaluation in advanced humanhead and neck cancer.
Authors: Elizabeth Ramsburg; Jean Publicover; Linda Buonocore; Amanda Poholek; Michael Robek; Amy Palin; John K Rose Journal: J Virol Date: 2005-12 Impact factor: 5.103
Authors: Marianne Nordsmark; Søren M Bentzen; Volker Rudat; David Brizel; Eric Lartigau; Peter Stadler; Axel Becker; Markus Adam; Michael Molls; Juergen Dunst; David J Terris; Jens Overgaard Journal: Radiother Oncol Date: 2005-08-10 Impact factor: 6.280
Authors: B Brockstein; D J Haraf; A W Rademaker; M S Kies; K M Stenson; F Rosen; B B Mittal; H Pelzer; B B Fung; M-E Witt; B Wenig; L Portugal; R W Weichselbaum; E E Vokes Journal: Ann Oncol Date: 2004-08 Impact factor: 32.976
Authors: Oliver Ebert; Katsunori Shinozaki; Chryssanthi Kournioti; Man-Seong Park; Adolfo García-Sastre; Savio L C Woo Journal: Cancer Res Date: 2004-05-01 Impact factor: 12.701
Authors: Laura Shulak; Vladimir Beljanski; Cindy Chiang; Sucharita M Dutta; Julien Van Grevenynghe; S Mehdi Belgnaoui; Thi Lien-Anh Nguyên; Thomas Di Lenardo; O John Semmes; Rongtuan Lin; John Hiscott Journal: J Virol Date: 2013-12-26 Impact factor: 5.103
Authors: Shawn T Beug; Stephanie J Pichette; Martine St-Jean; Janelle Holbrook; Danielle E Walker; Eric C LaCasse; Robert G Korneluk Journal: Mol Ther Oncolytics Date: 2018-06-21 Impact factor: 7.200